var data={"title":"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/contributors\" class=\"contributor contributor_credentials\">Arnold S Freedman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/contributors\" class=\"contributor contributor_credentials\">Jon C Aster, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/contributors\" class=\"contributor contributor_credentials\">Claire Dearden, MD, BSc, FRCP, FRCPath</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/contributors\" class=\"contributor contributor_credentials\">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/contributors\" class=\"contributor contributor_credentials\">Rebecca F Connor, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T cell prolymphocytic leukemia (T-PLL) is a rare T cell neoplasm composed of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, lymph nodes, and spleen. The name &quot;prolymphocyte&quot; is actually a misnomer, as the tumor cells in this disease are of post-thymic T cell origin. This class of neoplasms includes many cases previously classified as T cell chronic lymphocytic leukemia, a category no longer included in the current World Health Organization (WHO) classification.</p><p>The epidemiology, clinical presentation, pathology, and diagnosis of T-PLL are discussed here. The treatment of T-PLL is presented separately. (See <a href=\"topic.htm?path=treatment-of-t-cell-prolymphocytic-leukemia\" class=\"medical medical_review\">&quot;Treatment of T cell prolymphocytic leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T-PLL is an extremely rare disease, comprising approximately 2 percent of mature lymphocytic leukemias in adults [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/1\" class=\"abstract_t\">1</a>]. Sporadic T-PLL mainly affects the elderly with a mean age at presentation of 65 years [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/2\" class=\"abstract_t\">2</a>]. It has not been reported in children or young adults. There is a slight male predominance with a male:female ratio of 1.33 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Patients with ataxia telangiectasia have a greatly increased incidence of T-PLL with a different epidemiologic profile [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/4\" class=\"abstract_t\">4</a>]. In contrast to patients with sporadic T-PLL, the median age of onset of T-PLL in patients with ataxia telangiectasia is about 30 years of age, and some cases appear in adolescence [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=ataxia-telangiectasia\" class=\"medical medical_review\">&quot;Ataxia-telangiectasia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with T-PLL present with an elevated white blood count (typically <span class=\"nowrap\">&gt;100,000/microL),</span> hepatosplenomegaly (75 percent), and generalized lymphadenopathy (50 percent); anemia (36 percent) and thrombocytopenia (51 percent) can be seen, but are less common than in B cell prolymphocytic leukemia [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/3\" class=\"abstract_t\">3</a>]. In addition, skin infiltration and serous effusions (ie, pleural) occur in approximately 25 and 15 percent of patients, respectively [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/6\" class=\"abstract_t\">6</a>]. Involvement of the central nervous system is rare. Infrequently, asymptomatic patients are diagnosed as part of the evaluation of abnormal laboratory studies.</p><p>Pertinent negatives in the laboratory work-up of patients include the absence of paraproteinemia or evidence of infection with HTLV (human T lymphotropic virus) types 1 or 2.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">PATHOLOGY</span></p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Morphology</span></p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Peripheral blood and bone marrow</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Examination of the peripheral blood demonstrates a predominance of lymphoid cells (<a href=\"image.htm?imageKey=HEME%2F85962%7EHEME%2F64572\" class=\"graphic graphic_picture graphicRef85962 graphicRef64572 \">picture 1A-B</a>). There are three morphologic variants [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/3,6\" class=\"abstract_t\">3,6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Typical (75 percent) &ndash; The tumor cells are medium-sized lymphoid cells with moderately condensed chromatin and a visible nucleolus [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/1,6\" class=\"abstract_t\">1,6</a>]. The nucleus can be round or oval. The cytoplasm is usually moderately abundant and slightly basophilic without granules. Cytoplasmic protrusions (blebs) are common.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small cell variant (20 percent) &ndash; The tumor cells are small with condensed chromatin and a small nucleolus visible only by electron microscopy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cerebriform (S&eacute;zary cell-like) variant (5 percent) &ndash; The tumor cells have a very irregular nuclear outline resembling the cerebriform nucleus of S&eacute;zary cells seen in mycosis fungoides (<a href=\"image.htm?imageKey=HEME%2F75793\" class=\"graphic graphic_picture graphicRef75793 \">picture 2</a>).</p><p/><p>The bone marrow is infiltrated in an interstitial pattern by cells with similar morphology.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Skin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Skin infiltrations most commonly involve the trunk or the limbs and produce an erythematous maculopapular rash; nodular skin involvement may also be seen. T-PLL may also involve the face, where it manifests as purpura and edema, often in a periorbital distribution (<a href=\"image.htm?imageKey=HEME%2F85961\" class=\"graphic graphic_picture graphicRef85961 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Skin biopsy of affected areas demonstrates perivascular or diffuse dermal infiltrates, sometimes with accompanying hemorrhage, but without epidermotropism.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Other tissues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The spleen demonstrates dense lymphoid infiltrates in the red pulp that often invade the splenic capsule. The white pulp is usually atrophied. Lymph node involvement is diffuse, often with prominent high-endothelial venules. Infiltration typically involves the paracortical areas and may spare the follicles.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Immunophenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T-PLL cells express CD52 (strongly) and pan-T cell markers (CD2, CD3, and CD7) (<a href=\"image.htm?imageKey=HEME%2F85963\" class=\"graphic graphic_figure graphicRef85963 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/1\" class=\"abstract_t\">1</a>]. Terminal deoxynucleotidyl transferase (TdT) is not expressed. CD3 may be expressed on the cell membrane at low or high levels. Expression of CD4 and CD8 is variable: 60 percent of cases are <span class=\"nowrap\">CD4+/CD8-,</span> 25 percent of cases are <span class=\"nowrap\">CD4+/CD8+,</span> and 15 percent of cases are <span class=\"nowrap\">CD4-/CD8+</span>. The coexpression of CD4 and CD8 is practically unique to T-PLL among post-thymic T cell malignancies. T-PLL cells overexpress the oncogene TCL1 as demonstrated by immunohistochemistry.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Genetic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T cell receptor genes are clonally rearranged. Chromosomal abnormalities are common. Rearrangements involving TCL1 are common and relatively specific for T-PLL. These may take the form of either inv(14) or t(14;14)(q11;q32). Another abnormality, t(X;14)(q28;q11), involves a homolog of TCL1, MTCP1 (mature T cell proliferation 1 gene) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/1,4,9-12\" class=\"abstract_t\">1,4,9-12</a>]. Overall, approximately 90 percent of cases demonstrate chromosome abnormalities involving chromosome 14.</p><p>Other chromosomal or genetic abnormalities include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormalities in chromosome 8 (70 to 80 percent of cases) including idic(8p11), t(8;8), and trisomy 8q [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Del(12p13), abnormalities in chromosome 6 (33 percent) and chromosome 17 (26 percent), deletion of TP53 gene (17p13) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/4,13-15\" class=\"abstract_t\">4,13-15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Deletions of or missense mutations at the ataxia telangiectasia mutated (ATM) locus 11q23, a tumor suppressor gene that is inactivated by inherited germ line mutations in patients with ataxia telangiectasia [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/16,17\" class=\"abstract_t\">16,17</a>].</p><p/><p>Activating mutations in the JAK1 or JAK3 non-receptor tyrosine kinases occur in approximately one-third of cases [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/18,19\" class=\"abstract_t\">18,19</a>]. JAK mutations are not specific for T-PLL, as they also occur in a variety of other T cell neoplasms, but have raised interest in possible use of JAK inhibitors in T-PLL. Haploinsufficiency for the CDKN1B tumor suppressor gene is another common genetic lesion that occurs in approximately half of cases [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/20\" class=\"abstract_t\">20</a>]. A subset of cases also have been reported to have mutations in STAT5B, the small GTP-binding protein RHOA, and the epigenetic regulators EZH2, TET2, and BCOR, none of which are specific for T-PLL [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of T-PLL is usually made by evaluation of the peripheral blood, bone marrow biopsy and bone marrow aspirate in the appropriate clinical setting. When evaluated with flow cytometry and immunostains, these samples demonstrate a T cell immunophenotype. There is expression of CD52 and pan-T cell markers (CD2, CD3, and CD7), as well as overexpression of TCL1. Expression of CD4 and CD8 vary. Serologic and PCR (polymerase chain reaction) testing for human T-lymphotropic viruses (HTLV), type I is negative.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of T-PLL includes other chronic lymphoid neoplasms or T cell neoplasms with a leukemic presentation (<a href=\"image.htm?imageKey=HEME%2F56540\" class=\"graphic graphic_table graphicRef56540 \">table 1</a>). They are described in more detail below.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">B cell prolymphocytic leukemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>B cell prolymphocytic leukemia (B-PLL) has a similar clinical presentation and morphologic appearance to T-PLL. Skin infiltration and lymphadenopathy, which are unusual in B-PLL, are much more common in T-PLL. These two entities differ in their immunophenotype. Unlike T-PLL, B-PLL expresses one or more B cell antigens (CD20, CD22, FMC7, CD79a). (See <a href=\"topic.htm?path=b-cell-prolymphocytic-leukemia\" class=\"medical medical_review\">&quot;B cell prolymphocytic leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Mycosis fungoides/S&eacute;zary syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both T-PLL and mycosis fungoides (MF) are T cell neoplasms that can involve the blood and skin. The morphology of the &quot;cerebriform&quot; (S&eacute;zary cell-like) variant seen in 5 percent of patients with T-PLL resembles the S&eacute;zary cells seen in MF. MF is diagnosed using a diagnostic algorithm that incorporates clinical features, histology, immunophenotype, and molecular biology in a point-based system (<a href=\"image.htm?imageKey=HEME%2F74457\" class=\"graphic graphic_table graphicRef74457 \">table 2</a>). A diagnosis of MF is made when a total of four points or more is determined. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-sezary-syndrome\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Chronic lymphocytic leukemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both T-PLL and chronic lymphocytic leukemia (CLL) can present with lymphocytosis and splenomegaly, and have circulating prolymphocytes in the blood.</p><p>Typical CLL cells are small, mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, and without discernible nucleoli. There is a narrow border of clear to slightly basophilic cytoplasm (<a href=\"image.htm?imageKey=HEME%2F54469\" class=\"graphic graphic_picture graphicRef54469 \">picture 4</a>). Prolymphocytes usually comprise fewer than 10 percent of the circulating cells. Most importantly, CLL is a B cell neoplasm and demonstrates both expression of B cell associated antigens (CD19, CD20, and CD23) the T cell associated antigen CD5. T-PLL does not express B cell associated antigens. (See <a href=\"topic.htm?path=clinical-presentation-pathologic-features-diagnosis-and-differential-diagnosis-of-chronic-lymphocytic-leukemia\" class=\"medical medical_review\">&quot;Clinical presentation, pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Adult T cell leukemia-lymphoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adult T cell leukemia-lymphoma (ATL) is a peripheral T cell neoplasm associated with infection by the human T-lymphotropic virus, type I (HTLV-I). Serologic and PCR (polymerase chain reaction) testing for HTLV-I is used to exclude this diagnosis. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-adult-t-cell-leukemia-lymphoma\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Hairy cell leukemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cytoplasm of T-PLL can demonstrate cytoplasmic protrusions or blebs that may resemble the projections seen in the circulating tumor cells of hairy cell leukemia (HCL). Hairy cells strongly express pan-B cell antigens (CD19, CD20, CD22), and usually lack expression of CD5, CD10, CD21, and CD23. Hairy cells also characteristically express CD11c, CD25, CD103, CD123, cyclin D1, and annexin A1. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hairy-cell-leukemia\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of hairy cell leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">T cell large granular lymphocyte leukemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both T-PLL and T cell large granular lymphocyte (LGL) leukemia can present with a peripheral blood lymphocytosis. The tumor cells of LGL leukemia are characterized by their large size (15 to 18 microns), abundant cytoplasm containing typical azurophilic granules, a reniform or round nucleus, and a mature post-thymic immunophenotype. They express CD8 and CD57 with or without the expression of CD16 and the natural killer cell marker CD56 (<a href=\"image.htm?imageKey=HEME%2F80765\" class=\"graphic graphic_algorithm graphicRef80765 \">algorithm 1</a>). (See <a href=\"topic.htm?path=treatment-of-large-granular-lymphocyte-leukemia\" class=\"medical medical_review\">&quot;Treatment of large granular lymphocyte leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T-PLL is a highly aggressive T cell leukemia with a median survival less than one year [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/1\" class=\"abstract_t\">1</a>]. A minority of cases have a more chronic course [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/22\" class=\"abstract_t\">22</a>]. Such tumors typically express a memory T cell immunophenotype <span class=\"nowrap\">(CD45RO+/CD45RA-)</span>. Increased expression of TCL1 and the resultant increased activity of the serine-threonine kinase AKT appear to correlate with a worse outcome [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>T cell prolymphocytic leukemia (T-PLL) is a rare T cell neoplasm comprised of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, and spleen. It is most common in the elderly. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients typically present with an elevated white blood count (usually <span class=\"nowrap\">&gt;100,000/microL),</span> hepatosplenomegaly, and generalized lymphadenopathy. Skin infiltration and serous effusions are not uncommon. (See <a href=\"#H3\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of T-PLL is most often made by examination of the peripheral blood and bone marrow coupled with flow cytometry. When evaluated with flow cytometry and immunostains, these samples demonstrate a T cell immunophenotype. Tumor cells express high levels of CD52 and also express pan-T cell markers (CD2, CD3, and CD7) and TCL1. Serologic and polymerase chain reaction testing for human T-lymphotropic viruses, type I is negative. (See <a href=\"#H11\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of T-PLL includes other lymphoid neoplasms with a leukemic presentation. (See <a href=\"#H12\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Survival is usually less than one year despite therapy, but a more indolent variant may exist in a small subset of patients. Prognostic markers have been difficult to determine. (See <a href=\"#H19\" class=\"local\">'Prognosis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/2\" class=\"nounderline abstract_t\">Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986; 63:377.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/3\" class=\"nounderline abstract_t\">Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78:3269.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/4\" class=\"nounderline abstract_t\">Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991; 55:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/5\" class=\"nounderline abstract_t\">Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87:423.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/6\" class=\"nounderline abstract_t\">Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/7\" class=\"nounderline abstract_t\">Magro CM, Morrison CD, Heerema N, et al. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol 2006; 55:467.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/8\" class=\"nounderline abstract_t\">Herling M, Valbuena JR, Jones D, Medeiros LJ. Skin involvement in T-cell prolymphocytic leukemia. J Am Acad Dermatol 2007; 57:533.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/9\" class=\"nounderline abstract_t\">Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998; 103:110.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/10\" class=\"nounderline abstract_t\">Pekarsky Y, Hallas C, Isobe M, et al. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci U S A 1999; 96:2949.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/11\" class=\"nounderline abstract_t\">Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 1993; 8:2475.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/12\" class=\"nounderline abstract_t\">Hu Z, Medeiros LJ, Fang L, et al. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol 2017; 92:441.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/13\" class=\"nounderline abstract_t\">Hetet G, Dastot H, Baens M, et al. Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. Hematol J 2000; 1:42.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/14\" class=\"nounderline abstract_t\">Brito-Babapulle V, Hamoudi R, Matutes E, et al. p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. Br J Haematol 2000; 110:180.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/15\" class=\"nounderline abstract_t\">Costa D, Queralt R, Aymerich M, et al. High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer Genet Cytogenet 2003; 147:36.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/16\" class=\"nounderline abstract_t\">Stilgenbauer S, Schaffner C, Litterst A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997; 3:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/17\" class=\"nounderline abstract_t\">Vorechovsk&yacute; I, Luo L, Dyer MJ, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997; 17:96.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/18\" class=\"nounderline abstract_t\">Bergmann AK, Schneppenheim S, Seifert M, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2014; 53:309.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/19\" class=\"nounderline abstract_t\">Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 2014; 124:1460.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/20\" class=\"nounderline abstract_t\">Bellanger D, Jacquemin V, Chopin M, et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 2014; 28:417.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/21\" class=\"nounderline abstract_t\">L&oacute;pez C, Bergmann AK, Paul U, et al. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. Br J Haematol 2016; 173:265.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/22\" class=\"nounderline abstract_t\">Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Fran&ccedil;ais d'H&eacute;matologie Cellulaire. Br J Haematol 1998; 103:488.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-t-cell-prolymphocytic-leukemia/abstract/23\" class=\"nounderline abstract_t\">Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008; 111:328.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4745 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H20\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL FEATURES</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">PATHOLOGY</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Morphology</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Peripheral blood and bone marrow</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Skin</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Other tissues</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">Immunophenotype</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Genetic features</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">DIAGNOSIS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">B cell prolymphocytic leukemia</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Mycosis fungoides/S&eacute;zary syndrome</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Chronic lymphocytic leukemia</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Adult T cell leukemia-lymphoma</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Hairy cell leukemia</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">T cell large granular lymphocyte leukemia</a></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">PROGNOSIS</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/4745|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=HEME/80765\" class=\"graphic graphic_algorithm\">- Evaluation for LGL</a></li></ul></li><li><div id=\"HEME/4745|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/85963\" class=\"graphic graphic_figure\">- T-PLL flow cytometry</a></li></ul></li><li><div id=\"HEME/4745|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/85962\" class=\"graphic graphic_picture\">- T-PLL morphology</a></li><li><a href=\"image.htm?imageKey=HEME/64572\" class=\"graphic graphic_picture\">- T PLL blood smear</a></li><li><a href=\"image.htm?imageKey=HEME/75793\" class=\"graphic graphic_picture\">- Sezary cells mycosis fungoides</a></li><li><a href=\"image.htm?imageKey=HEME/85961\" class=\"graphic graphic_picture\">- Clinical features T-PLL</a></li><li><a href=\"image.htm?imageKey=HEME/54469\" class=\"graphic graphic_picture\">- CLL smear</a></li></ul></li><li><div id=\"HEME/4745|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/56540\" class=\"graphic graphic_table\">- DDx TPLL path</a></li><li><a href=\"image.htm?imageKey=HEME/74457\" class=\"graphic graphic_table\">- Diagnosis early mycosis fungoides</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=ataxia-telangiectasia\" class=\"medical medical_review\">Ataxia-telangiectasia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=b-cell-prolymphocytic-leukemia\" class=\"medical medical_review\">B cell prolymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hairy-cell-leukemia\" class=\"medical medical_review\">Clinical features and diagnosis of hairy cell leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-adult-t-cell-leukemia-lymphoma\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-pathologic-features-and-diagnosis-of-sezary-syndrome\" class=\"medical medical_review\">Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-pathologic-features-diagnosis-and-differential-diagnosis-of-chronic-lymphocytic-leukemia\" class=\"medical medical_review\">Clinical presentation, pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-t-cell-prolymphocytic-leukemia\" class=\"medical medical_review\">Treatment of T cell prolymphocytic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-large-granular-lymphocyte-leukemia\" class=\"medical medical_review\">Treatment of large granular lymphocyte leukemia</a></li></ul></div></div>","javascript":null}